SCHEMBL7039693

SCHEMBL7039693

CC(C)c1ccc(S(=O)(=O)NCCO)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
CYP2C19 P33261 2/20 0.58
GAA P10253 1/20 0.53
PKM P14618 1/20 0.53
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
IKBKB O14920 1/20 0.51
CHUK O15111 1/20 0.51
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
CYP2D6 P10635 1/20 0.46
POLB P06746 1/20 0.46
F10 P00742 1/20 0.46
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15801264 0.90 ALDH1A1 (0.55) ALDH1A1CYP2C19GAAPKMRAB9A
SCHEMBL7621847 0.85 ALDH1A1 (0.75) ALDH1A1CYP2C19GAAPKMRAB9A
SCHEMBL10463157 0.85 RAB9A (0.61) ALDH1A1RAB9ASMN1; SMN2LMNACA12
SCHEMBL14132270 0.85 ALDH1A1 (0.59) ALDH1A1CYP2C19GAARAB9ASMN1; SMN2
SCHEMBL9229020 0.84 CA1 (0.69) ALDH1A1CYP2C19RAB9ASMN1; SMN2LMNA
SCHEMBL14298921 0.83 ALDH1A1 (0.55) ALDH1A1CYP2C19GAAPKMRAB9A
SCHEMBL23693484 0.83 CYP3A4 (0.69) ALDH1A1GAAPKMRAB9ASMN1; SMN2
SCHEMBL26212905 0.83 ALDH1A1 (0.53) ALDH1A1PKMRAB9ASMN1; SMN2LMNA
SCHEMBL9228822 0.81 LMNA (0.56) ALDH1A1GAAPKMRAB9ASMN1; SMN2
SCHEMBL24721309 0.81 IKBKB (0.51) ALDH1A1CYP2C19GAAPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20210338610-A1 AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF HEPANOVA, INC. 2021-11-04 US disclosed
US-10626111-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-04-21 US disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-07 US disclosed
US-8324207-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
US-20110306607-A1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-15 US disclosed
EP-1045045-B1 Composition and process for the conditioning of water for industrial use FABORGA SA (CH) 2003-03-26 EP disclosed
EP-1045045-A1 Composition and process for the conditioning of water for industrial use FABORGA S.A. (CH) 2000-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885CYP2C19 4848/4885GAA 2227/4885
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels KCNJ2, TRPV1, KCNJ1 ALDH1A1 1614/4885CYP2C19 2882/4885GAA 2915/4885
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 ALDH1A1 1985/4885CYP2C19 1772/4885GAA 387/4885
US-20110306607-A1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, TRPV1, KCNJ1 ALDH1A1 1614/4885CYP2C19 2882/4885GAA 2915/4885
US-10626111-B2 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 ALDH1A1 1991/4885CYP2C19 1431/4885GAA 339/4885
US-20210338610-A1 AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF AADAC, GOT2, ABAT ALDH1A1 342/4885CYP2C19 669/4885GAA 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.